In the BioHarmony Drug Report Database

"Preview" Icon

Atezolizumab

Tecentriq (atezolizumab) is an antibody pharmaceutical. Atezolizumab was first approved as Tecentriq on 2016-05-18. It is used to treat non-small-cell lung carcinoma and urinary bladder neoplasms in the USA. It has been approved in Europe to treat breast neoplasms, non-small-cell lung carcinoma, small cell lung carcinoma, transitional cell carcinoma, and urologic neoplasms. The pharmaceutical is active against programmed cell death 1 ligand 1.

 

Trade Name

 

Tecentriq
 

Common Name

 

atezolizumab
 

ChEMBL ID

 

CHEMBL3707227
 

Indication

 

breast neoplasms, non-small-cell lung carcinoma, small cell lung carcinoma, transitional cell carcinoma, urinary bladder neoplasms, urologic neoplasms
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Atezolizumab structure rendering